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Abstract 
Background and aim Synthetic cannabinoids (SCs) are consumed as legal alternative to cannabis and often 
allow passing drug-screening tests. Their rapid transience on the drug scene, combined with their mostly 
unknown metabolic profiles, creates a scenario with constantly moving analytical targets, making their 
monitoring and identification challenging. The development of fast screening strategies for SCs, not 
directly focused on their chemical structure, as an alternative to the commonly applied target acquisition 
methods, would be highly appreciated in forensic and public health laboratories. Methods An innovative 
untargeted metabolomics approach, focused on herbal components commonly used for `spice´ products, 
was applied. Saliva samples of healthy volunteers were collected at pre-dose and after smoking herbal 
components and analyzed by high-resolution mass spectrometry. Results The data obtained, combined 
with appropriate statistical analysis, allowed to highlight and elucidate two markers (Scopoletin and N,N-
bis(2-hydroxyethyl)dodecylamine), which ratio permitted to differentiate herbal smokers from non-
smokers. Conclusions The proposed strategy will allow discriminating potential positives, on the basis of 
the analysis of two markers identified in the herbal blends. This work is presented as a step forward in SC 
drug testing, promoting a smart first-line screening approach, which will allow reducing the number of 
samples to be further investigated by more sophisticated HRMS methods. 
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Introduction 
New synthetic cannabinoids (SCs) are introduced each year into the international `market´ as legal 
alternative to cannabis (1,2). Although they are structurally unrelated, SCs act functionally similar to Δ9-
tetrahydrocannabinol (THC) i.e. the principal active component of cannabis. Branded herbal or `spice´ 
products, containing SCs, are easily purchased through online vendors and smart shops, where they are 
sold with misleading information about their effects and safety. Hence, SCs are considered a growing 
problem and are associated with severe negative effects in consumer’s health (3–5).  
The impetus of smoking herbal products, adulterated with SCs, is often not only to get intoxicated legally, 
but it also enables users to pass drug-screening tests. The latter is an important element for any setting 
where drug abstinence control is obligatory e.g. specific psychiatry or prison settings, driving liability 
testing or employment drug testing procedures (1). 
The detection and identification of SCs is an analytical challenge due to their rapid transience on the drug 
scene (6,7). This fact combined with the mostly unknown and extensive metabolic pathways has created 
a scenario, where a high number and constantly moving analytical targets need to be considered for a 
comprehensive investigation of SCs consumption. Around 170 SCs have been reported until 2017 to the 
Early Warning System of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), a 
number that will surely increase in the next years. In addition, analytical reference standards are not 
always available or it takes much time to purchase them. This has triggered analytical chemists to develop 
comprehensive screening strategies mostly based on high-resolution mass spectrometry (HRMS), 
employing suspect and non-targeted approaches (8,9). HRMS has shown strong potential to screen for 
large lists of target compounds,  as well as unknown substances, including in a retrospective manner 
(8,10). Its strong potential for identification and elucidation of compounds relies on accurate-mass full-
spectrum data, but HRMS-based methods also have limitations in capacity and sensitivity (11), and data 
processing is very laborious and time consuming, which makes it increasingly challenging and costly when 
numerous samples need to be analysed.   
The development of alternative, fast and generic screening methods, not directly focused on the analyte 
chemical structure, is an attractive approach that would facilitate the complex analytical scenario and 
provide fast response on potential SC consumption. Recently, Canneart et al. developed an assay that 
allowed activity profiling of SCs and their metabolites (11). This activity-based assay might serve as a first-
line screening tool of urine, complementing conventional targeted and untargeted analytical methods. 
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This strategy does not allow the direct identification of SCs, but is neither limited to a given list of 
compounds, oppositely to the target approaches, which may lead to reporting false negatives when the 
compound (parent drug or metabolite) is not included in the candidate list. 
In this work, we apply an innovative untargeted metabolomics approach for the rapid monitoring of SCs 
consumption. The strategy applied is focused on the main natural herbal components used for `spice´ 
products. Thus, instead of screening for target SCs or unknown substances, identified markers of herbs 
can be monitored to flag suspect samples, since these herbs are commonly used as the herbal base for 
the active synthetic chemical ingredients (12). We present the proof-of-principle of this original strategy 
directed towards saliva samples instead of urine. The collection of a saliva samples is fast, easy and non-
invasive, it is also less prone to fraud with respect to urine samples, especially essential in obligatory drug 
control settings.   
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Material and Methods 
Chemicals and reagents  
HPLC-grade water was obtained by purifying demineralized water in a Mili-Q plus system from Millipore 
(Bedford, MA, USA). HPLC-grade acetonitrile (ACN), methanol (MeOH), and ammonium acetate (NH4Ac) 
were acquired from Scharlab S.L. (Barcelona, Spain). Leucine-enkephalin, formic acid (HCOOH, 98 - 100 
%), Scopoletin (99% purity) and N,N-bis(2-hydroxyethyl)dodecylamine (99% purity) were purchased from 
Sigma-Aldrich (Augsburg, Germany). 
Six natural herbal components Canavalia maritima, Leonurus sibiricus, Althaea officinalis, Turnera diffusa, 
Verbascum thapsus, Calendula officinalis were purchased from Worldherbals (Vlaardingen, the 
Netherlands). Tobacco from different trademarks (Domingo, Fortuna and Camel) was purchased from a 
local tobacconist. 
 
Sample collection and treatment 
Hand-rolled cigarettes containing 0.5 g of tobacco or mixtures of 0.25 g herb with 0.25 g of tobacco (50:50, 
w/w), were prepared. Each mixture contained tobacco and solely one herbal component. Three healthy 
volunteers smoked the tobacco cigarette and six herbal mixtures, leaving three days between 
experiments. Saliva samples were collected in an Eppendorf tube before (at pre-dose, t = 0) and after 
smoking (t = 30 minutes), and immediately stored in the dark at −20 °C until analyses (within 1 week). The 
volunteers were informed, and were involved in the study protocol design, giving their consent.  
Prior to analyses, saliva samples were thawed, and 0.5 mL sample was vortexed for 1 min. Subsequently, 
1 mL of ACN was added, vortexed for 30 sec, sonicated for 1 min and centrifuged at 10.000 g for 10 min. 
Supernatant was led to dryness under vacuum and reconstituted in 50 µL of H2O:ACN (90:10 v/v)(13). 
Quality control samples (QCs), consisting in a mix of all saliva extracts (blanks and smoked), as well as the 
sample extracts (10µL) were injected directly into the UHPLC-QTOF MS system. 
 
Instrumentation  
A Waters Acquity UPLC system (Waters Corp., Milford, MA, USA) was interfaced to a hybrid quadrupole- 
orthogonal acceleration- ToF mass spectrometer (Xevo G2 QTof, Waters Corp., Manchester, UK) using a 
Z-spray electrospray ionization (ESI) interface operating in both positive and negative ionization modes. A 
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capillary voltage of 0.7 kV for ESI+ and 1.5 kV for ESI- mode, and a cone voltage of 20 V were used. MSE 
data were acquired over the range m/z 50–1200. MS/MS experiments were performed applying a collision 
energy of 10, 20 and 30 eV. 
The chromatographic separation was performed using a CORTECS® C18 fused core column (2.7 µm particle 
size, 2.1x100 mm) at a flowrate of 0.3 mL/min. The mobile phases used were A - MilliQ water and B - 
MeOH (both with 0.01% HCOOH). The total run time was 18 min.  
Further details on instrument operating conditions both chromatographic and spectrometric can be found 
elsewhere (10). 
 
Data processing  
Data (*.raw) were converted to a machine independent format (*.cdf) using the DataBridge application 
within MassLynxTM (Waters Corp., Milford, MA, USA). The converted data was then processed using XCMS 
free R package. Peak picking was performed with centWave, an algorithm for feature selection, which 
integrates area, considering a peak width between 4-20 sec., ≥ 3 scans with more than 1000 counts, s/n 
ratio of 10, and a mass error of ≤ 15 ppm. Peaks were grouped in single features using the retcor() function 
based on their retention time and mass error (an initial variation < 15 seconds and < 10 ppm between 
samples along the batch was considered as the same feature). Features were labelled as MXXXTYYY where 
XXX corresponds to the nominal Mass of peak XXX while YYY matches the retention Time in seconds. 
Samples were log2 transformed to reduce heteroscedasticity. Pareto scaling was applied before importing 
the data for statistical analysis. 
 
Statistical analysis 
Multivariate analysis was carried out using EZinfo 2.0 (Umetrics – Sartoris Stedim Biotech, Malmö, 
Sweden). First, Principal Component Analysis (PCA) was applied to ensure that the data was correctly 
acquired in both positive and negative ionization mode. Next, all data were merged in a single table for 
further statistical analysis. Partial Least Squares Discriminant Analysis (PLS-DA) was carried out to ensure 
that samples can be differentiated. Orthogonal Partial Least Squares – Discriminant Analysis (OPLS-DA) 
was performed in order to extract a small group of markers to differentiate between herb and tobacco.   
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Results and Discussion 
Six natural herbal components commonly used as the herbal base for ‘spice’ products were selected 
(1,14). The SCs are typically blended with or sprayed onto these herbs (12).   
Hand-rolled herb cigarettes were prepared as a mixture of tobacco and herb (50:50, w/w). Although 
differences between “only herb and only tobacco” saliva samples would possibly be more pronounced, 
tobacco could mask the markers for herbs, as cannabis (and very likely SCs as well) is often mixed with 
tobacco or consumed in parallel (15). Thus, a strategy focused on discriminating between saliva after 
smoking tobacco and herb-tobacco mixtures would allow a first screening of potential positive samples 
containing SCs.  
Saliva samples were collected using the same material of the same batch to avoid misinterpretations on 
assignment of potential markers. During experimental days, the volunteers did not have a strict diet. Since 
all samples collected from the three volunteers were processed at the same time, differences in diet were 
compensated and the selected markers could therefore be linked to herb and/or tobacco smoking. 
Metabolomics enables to discover and highlight differences between subject groups based on the 
powerful analytical capabilities of HRMS and bioinformatics (16–18). Hence, in this study, an untargeted 
metabolomics approach has been applied as a data-mining tool, to distinguish between tobacco and herb-
tobacco mixtures administration. HRMS data was processed and grouped by multiple peak picking 
functions and statistical tools, considering retention time and mass error. PCA analysis allowed to 
eliminate possible outliers (Hotelling’s T2 Ellipse (0.95)) and control the possible instrumental drift along 
the time. The latter could be done by injecting QCs in the initial part of the batch and after every 10 
samples. The QCs (n= 6) were grouped in the center of the PCA plot, indicating the correct acquisition of 
the data. Further statistical analysis by means of PLS-DA modelling showed differences in saliva samples 
at pre-dose (blank) and after smoking herbs or tobacco (72 % of variance for the first 2 components) 
(figure 1A). An S-Plot from OPLS-DA, representing all features, permitted to highlight the best two markers 
(figure 1B).  
The ratio between the peak area of these two features was evaluated achieving the discrimination 
between the blank and/or tobacco saliva samples versus the six different herb samples (figure 2). A 
threshold value of 0.02 could be set (figure 2, insert), meaning that samples with a ratio > 0.02 can be 
flagged as suspects.  
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The elemental compositions of the two most significant markers, retrieved from OPLS-DA, were calculated 
based on their accurate masses. Subsequently, tandem mass spectrometry (MS/MS) QTOF experiments 
were performed in order to obtain accurate-mass product-ion spectra. This information was used to 
search for plausible structures in available mass spectra libraries (Metlin and Massbank), chemical 
databases (Chemspider), and in-silico fragmentation web sources (MetFrag). Figure 3 shows the accurate-
mass product-ion spectra acquired at a collision energy of 30 eV. The accurate mass of the protonated 
molecules (mass error < 3 ppm) and of the fragment ions allowed the tentative identification of Scopoletin 
(marker 1; figure 3 top) and N,N-Bis(2-hydroxyethyl)dodecylamine (marker 2; figure 3 bottom), which 
were subsequently confirmed by the acquisition of the reference standards.  
 
Conclusions and future perspectives 
In this work, we present an innovative analytical strategy to obtain fast response on potential SC 
consumption. The application of an untargeted metabolic approach, based on the screening of saliva 
samples after consumption of tobacco and herbal components commonly used for spicing with SCs, has 
revealed two biomarkers (scopoletin and N,N-Bis(2-hydroxyethyl)dodecylamine). The ratio between 
these two biomarkers in all six herbs investigated permitted to discriminate between “tobacco and herb-
tobacco mixture” samples. By monitoring their ratio in saliva samples, a value above 0.02 reveals the 
smoking of herbs, and therefore suggesting, indirectly, the potential consumption of SCs. In this way, 
samples can be pre-selected for further profound HRMS investigation in order to identify the consumed 
SCs.  
We provide the proof-of-principle for this new approach, which can be considered as an important step 
forward towards a more generic SC drug test, not directly based on their structures, but on the herbal 
markers. However, in order to reach that goal future research is needed. This should be focused on the 
following issues: (i) to understand the significance of the selected biomarkers (already confirmed by their 
reference standards) and their link to the composition of the herbs investigated; (ii) full validation of the 
approach suggested, considering more volunteers and time/data points in order to evaluate more 
accurately the overall smoke/blood/saliva distribution of the markers;  (iii) evaluation of the ratio for the 
identified markers after smoking other herbs also used as herbal base (i.e. Nymphaea alba, Scutellaria 
lateriflora, Zornia latifolia, Nelumbo nucifera, Trifolium pratense, Leonotis leonurus, Astragallus root, 
Lamiaceae herbs and Rosa canina (12)); (iv) development of target analytical methods for the identified 
biomarkers in saliva, e.g. based on LC-MS/MS with triple quadrupole.  
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The strategy suggested is the target analysis (e.g. by LC-MS/MS QqQ) of identified herb biomarkers i.e. 
indirect indicators of SC consumption, and the subsequent monitoring of their peak area ratio. This 
approach has two major advantages: i) only positive/suspect samples need further investigation to 
identify the SCs smoked, which is more rapid and cost-effective since time-consuming analysis and data 
processing of all samples is avoided. ii) fraudulence in drug-screening tests by SCs consumers becomes 
more difficult, because monitoring is not based on the chemical structures of individual target SCs, but on 
the herbs markers. Therefore, it bypasses the fast-changing nature of the SCs market, where the current 
applications of target analysis might lead to reporting false negatives. In addition, this untargeted 
metabolomics approach could be applied to other matrices such as breath, hair and urine (19,20) for a 
similar purpose. This might allow the detection of SC consumption over a longer period of time, opening 
new possibilities for the laboratories to face the complex issue of monitoring the SCs market.  
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Figure captions 
Figure 1: A) PLS-DA 3D score plot for the first three components. B) S-Plot from OPLS-DA where 
all features are represented 
Figure 2: Boxplot representing ratios of the peak areas between marker 1 and marker 2 in the 
saliva samples i.e. blank and after tobacco and herb smoking (n= 24, 6, 18, 
respectively). Insert; zoom at ratios 0 to 0.15 
Figure 3: Identification by QTOF operating in MS/MS acquisition mode of Scopoletin (top) and 
N,N-Bis(2-hydroxyethyl)dodecylamine (bottom) in saliva samples. (Inserts: structure, 
chemical formula and exact mass of the protonated molecule)   
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